Revaxis®

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, GlaxoSmithKline, University Hospital, Geneva

Conditions

Acellular PertussisDiphtheriaPertussisPoliomyelitisTetanusVaccine-Preventable Diseases

Phase 2

Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines

University Hospital, GenevaPertussis, Vaccine-Preventable Diseases

Start: 2022-02-07End: 2023-03-30Target: 100Updated: 2022-01-18

Phase 3

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

CompletedNCT00447525

Sanofi Pasteur, a Sanofi CompanyDiphtheria, Poliomyelitis, Tetanus

Start: 2007-02-28End: 2008-01-31Updated: 2017-09-11

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

CompletedNCT01277705

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus

Start: 2002-01-31End: 2002-04-30Updated: 2016-09-07

Related Papers

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.

2015-04-144 citations